Skip to main content

ASCO Meeting 2023

Ph III study of QL1706 with chemotherapy as first-line in PD-L1 negative advanced or metastatic NSCLC

QL1706(PSB205) – Abstract #TPS9139

RETURN TO PRESENTATIONS